Maryam Nisar, Sajid Mushtaq, Usman Hassan, Noreen Akhtar, Muhammad Azma


Background: The objective of the study is to analyze the expression of androgen, estrogen and progesterone receptor in different types of endometrial carcinomas and to correlate the androgen receptor expression with estrogen and progesterone receptor and the clinicopathological parameters like  lymphovascular invasion, grade of the tumour, size of tumour and extent of myometrial invasion. Methods: It is a cross-sectional analytical study design with a simple random sample of a total of 54 cases of different types of endometrial carcinomas from the year 2017.  Immunohistochemical stains androgen receptor, estrogen receptor, and Progesterone receptor were applied in all the cases. The Pearson Chi-square test of independence was applied to measure association and P-value is calculated to check the significance of the results. Results: Androgen receptor expression was observed in 73% of low-grade endometrioid carcinomas, 62.5% of high-grade endometrioid carcinomas, 62% of serous, 20% of clear cell and 18% of carcinosarcomas, respectively. Androgen positive tumours were also positive for estrogen and progesterone in most of the cases, except 3 serous carcinomas and one low-grade endometrioid carcinoma. However, no significant relation was observed between androgen expression and prognostic parameters like the lymphovascular invasion, size of the tumour and myometrial invasion. Conclusion: Maximum expression of androgen receptor was observed in endometrioid and serous carcinomas, while carcinosarcomas and clear cell carcinomas showed minimum expression with no significant correlation between androgen receptor expression and clinicopathological parameters.

Keywords: Endometrioid carcinoma; Serous carcinoma; Clear cell carcinoma; Androgen receptor; Immunohistochemical stains

Full Text:



Gibson DA, Simitsidellis I, Collins F, Saunders PT. Evidence of androgen action in endometrial and ovarian cancers. Endocr Relat Cancer 2014;21(4):T203–18.

Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67–73.

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113(2):299–310.

Zadeh SL, Duska LR, Mills AM. Androgen receptor expression in endometrial carcinoma. Int J Gynecol Pathol 2018;37(2):167–73.

Bender D, Buekers T, Leslie K. Hormones and receptors in endometrial cancer. Proc Obstet Gynecol 2011;2(1):1–25.

Ito K, Utsunomiya H, Yaegashi N, Sasano H. Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer. Endocr J 2007:54(5):667–79.

Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Øyan AM, et al. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget 2016;7(31):49289–92.

Mahdi Z, Abdulfatah E, Pardeshi V, Hassan O, Schultz D, Morris R, et al. The impact of androgen receptor expression on endometrial carcinoma recurrence and survival. Int J Gynecol Pathol 2017;36(5):405–11.

Hashmi AA, Hussain ZF, Qadri A, Irfan M, Ramzan S, Faridi N, et al. Androgen receptor expression in endometrial carcinoma and its correlation with clinicopathologic features. BMC Res Notes 2018;11(1):289.

Asano Y, Kashiwagi S, Goto W, Tanaka S, Morisaki T, Takashima T, et al. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers (Basel) 2017;9(1):pii:E4.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, et al. Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. J Urol 2018;200(5):956–66.

Kamal AM, Bulmer JN, DeCruze SB, Stringfellow HF, Martin-Hirsch P, Hapangama DK. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br J Cancer 2016;114(6):688–96.

Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumo Biol 2011;32(3):451–9.

Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol 2008;21(9):1147–55.

Wei JJ, Paintal A, Keh P. Histologic and immunohistochemical analyses of endometrial carcinomas: experiences from endometrial biopsies in 358 consultation cases. Arch Pathol Lab Med 2013;137(11):1574–83.

Choi JE, Kang SH, Lee SJ, Bae YK. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 2015;22(1):82–9.

Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011;20(1):119–31.

Munoz J, Wheler JJ, Kurzrock R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget 2015;6(2):592–603.


  • There are currently no refbacks.

Contact Number: +92-992-382571

email: [jamc] [@] []